Low Dose Computed Tomography of the Whole Body

PROCEDURE2 trials

Sponsors

Mayo Clinic

Conditions

Multiple MyelomaPlasma Cell MyelomaRecurrent Plasma Cell MyelomaRefractory Plasma Cell Myeloma

Phase 1

Belantamab Mafodotin, Lenalidomide, and Daratumumab for the Treatment of Relapsed, Refractory, or Previously Untreated Multiple Myeloma

TerminatedNCT04892264

Mayo ClinicPlasma Cell Myeloma, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma

Start: 2021-06-03End: 2024-03-18Updated: 2025-05-18

MC210808 Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven-Rd), Daratumumab and Dexamethasone (Ven-Dd), or Daratumumab-Lenalidomide-Dexamethasone (Ven-DRd) for the Treatment of Multiple Myeloma

Active, not recruitingNCT06042725

Mayo ClinicMultiple Myeloma

Start: 2024-04-11End: 2027-05-29Updated: 2026-08-17